[
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either […]",
    "url": "https://finnhub.io/api/news?id=7b22c59b74a3985608c5d8cb5e2b571c31fdfb128ab19252d729620a0714d895",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765384118,
      "headline": "Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica",
      "id": 137749822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either […]",
      "url": "https://finnhub.io/api/news?id=7b22c59b74a3985608c5d8cb5e2b571c31fdfb128ab19252d729620a0714d895"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Plans $6B Investment in New Alabama Manufacturing Site",
    "summary": "Project aims to boost supply of next-generation obesity drugs as demand keeps climbing.",
    "url": "https://finnhub.io/api/news?id=5b0014009a1b658dca1e52461be0abdc1ccd0aa16603fa1804e526fb44107c49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765382027,
      "headline": "Eli Lilly Plans $6B Investment in New Alabama Manufacturing Site",
      "id": 137749823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Project aims to boost supply of next-generation obesity drugs as demand keeps climbing.",
      "url": "https://finnhub.io/api/news?id=5b0014009a1b658dca1e52461be0abdc1ccd0aa16603fa1804e526fb44107c49"
    }
  },
  {
    "ts": null,
    "headline": "Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?",
    "summary": "Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.",
    "url": "https://finnhub.io/api/news?id=54ea2aa0f995641b63e3c80d633c819b7ab97d03c41d33e7ab42e4bc2faa8513",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765379820,
      "headline": "Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?",
      "id": 137749824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.",
      "url": "https://finnhub.io/api/news?id=54ea2aa0f995641b63e3c80d633c819b7ab97d03c41d33e7ab42e4bc2faa8513"
    }
  },
  {
    "ts": null,
    "headline": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
    "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
    "url": "https://finnhub.io/api/news?id=c5951110279522e0c97ea2cd7f2fb0de73510d3aa02f717d2eb22d2782cd32ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765370580,
      "headline": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
      "id": 137749825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
      "url": "https://finnhub.io/api/news?id=c5951110279522e0c97ea2cd7f2fb0de73510d3aa02f717d2eb22d2782cd32ed"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Invest $6 Billion in New Alabama Manufacturing Plant",
    "summary": "Project expands U.S. production capacity as demand for weight-loss drugs grows",
    "url": "https://finnhub.io/api/news?id=21b05ba1565fc94ae2616a7e6eaa46dbd7b92a205367c8753c4a9bd9a8bd8ae8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765365984,
      "headline": "Eli Lilly to Invest $6 Billion in New Alabama Manufacturing Plant",
      "id": 137749826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Project expands U.S. production capacity as demand for weight-loss drugs grows",
      "url": "https://finnhub.io/api/news?id=21b05ba1565fc94ae2616a7e6eaa46dbd7b92a205367c8753c4a9bd9a8bd8ae8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility",
    "summary": "The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.",
    "url": "https://finnhub.io/api/news?id=42df374ed5e2ccd35ae6d5e400c760d4b21e5881caf8764b7663bdc5bb8447ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765365641,
      "headline": "Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility",
      "id": 137749827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.",
      "url": "https://finnhub.io/api/news?id=42df374ed5e2ccd35ae6d5e400c760d4b21e5881caf8764b7663bdc5bb8447ea"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
    "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
    "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362409,
      "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
      "id": 137747724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307043297/image_1307043297.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
      "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29"
    }
  },
  {
    "ts": null,
    "headline": "Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk",
    "summary": "Explore undervalued Novo Nordisk (NVO) vs. Eli Lilly, key growth insights, and investment risks.",
    "url": "https://finnhub.io/api/news?id=614c134a33e647cb51682ced84828d369bf8c32664de7c0902784ed0e04eab7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765359546,
      "headline": "Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk",
      "id": 137747549,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182825316/image_182825316.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Explore undervalued Novo Nordisk (NVO) vs. Eli Lilly, key growth insights, and investment risks.",
      "url": "https://finnhub.io/api/news?id=614c134a33e647cb51682ced84828d369bf8c32664de7c0902784ed0e04eab7b"
    }
  },
  {
    "ts": null,
    "headline": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
    "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
    "url": "https://finnhub.io/api/news?id=701171b3f0cb112052a3cc2baae99d53e3c380d6abf5955fae89c5ae952cdc52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765359000,
      "headline": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
      "id": 137749828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
      "url": "https://finnhub.io/api/news?id=701171b3f0cb112052a3cc2baae99d53e3c380d6abf5955fae89c5ae952cdc52"
    }
  },
  {
    "ts": null,
    "headline": "The Fed meeting, pressure on Oracle, Target's fashion-forward renovation and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=94201dd50dfa8a410879a0315099aaa24a98694add1d31412bc1d2725be05fad",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765353820,
      "headline": "The Fed meeting, pressure on Oracle, Target's fashion-forward renovation and more in Morning Squawk",
      "id": 137748288,
      "image": "https://image.cnbcfm.com/api/v1/image/108219013-1761772288767-gettyimages-2243505194-POWELL_FOMC_NYSE.jpeg?v=1765331525&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=94201dd50dfa8a410879a0315099aaa24a98694add1d31412bc1d2725be05fad"
    }
  }
]